CytoSeek

CytoSeek is a discovery-stage biotech company located in Bristol, UK, founded in 2017 as a spin-out from the University of Bristol.

The company focuses on developing next-generation cell therapies for cancer, particularly targeting solid tumors, using its proprietary Artificial Membrane-Binding Protein (AMBP) technology. The AMBP technology acts as a modular protein-based "cellular paint" that enhances the functionality of therapeutic cells. It binds to the plasma membrane of various cell types, delivering therapeutic peptides, proteins, or enzymes that improve tissue-specific targeting, cell survivability, and the ability of immune cells to penetrate tumor microenvironments. CytoSeek is currently engaged in preclinical proof-of-principle studies and aims to partner with cell therapy companies to bring its innovative products to clinical use. With a mission to enhance human health through advanced therapies, CytoSeek is also exploring potential applications in heart disease and osteoarthritis. The company is led by CEO Carolyn Porter and COO Ben Carter, and it has raised significant funding to support its research and development efforts in the oncology sector.